RBM9 (E7W6U) Rabbit mAb #37315
- WB
- IP
Supporting Data
| REACTIVITY | H Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 50, 60 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Protocol
Specificity / Sensitivity
RBM9 (E7W6U) Rabbit mAb recognizes endogenous levels of total RBM9 protein. This antibody detects multiple isoforms of RBM9.
Species Reactivity:
Human, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala77 of human RBM9 protein.
Background
RBM9, also known as RBFOX2, is an RNA-binding protein involved in the regulation of tissue specific alternative splicing (1). RBM9 is widely expressed in many tissues throughout various developmental stages. Several isoforms of this protein are generated by variable use of multiple alternatively spliced internal exons and alternative splice sites (2-4). RBM9 is predominantly localized in the nucleus, where it regulates alternative pre-mRNA splicing. This factor was also identified to be a novel constituent of cytoplasmic stress granules (SGs), and its RNA binding activity is necessary for its localization into SGs (5). Notably, RBM9 dissociation from SGs suppresses cancer progression (6). The splicing-regulatory role of RBM9 has also been implicated as a tumor suppressor in pancreatic ductal adenocarcinoma (PDA) and could serve as a therapeutic approach for metastatic PDA (7).
- Arya, A.D. et al. (2014) Biochem Soc Trans 42, 1180-3.
- Jin, Y. et al. (2003) EMBO J 22, 905-12.
- Kim, K.K. et al. (2011) Nucleic Acids Res 39, 3064-78.
- Nakahata, S. and Kawamoto, S. (2005) Nucleic Acids Res 33, 2078-89.
- Park, C. et al. (2017) Sci Rep 7, 11211.
- Choi, S. et al. (2019) Exp Mol Med 51, 1-12.
- Jbara, A. et al. (2023) Nature 617, 147-153.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.